FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Translational Cancer Research

• Publication date

  2025-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/tcr-2024-2589PMID 40687261PMCID 12268507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA.

  2025cited by this paper
• Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study.

  2024cited by this paper
• Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)

  2024cited by this paper
• Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

  2024cited by this paper
• Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

  2023cited by this paper
• CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

  2023cited by this paper
• Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

  2023cited by this paper
• Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

  2023cited by this paper
• Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study.

  2023cited by this paper
• The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

  2022cited by this paper
• Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort.

  2022cited by this paper
• Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.

  2022cited by this paper
• Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

  2022cited by this paper
• Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

  2020cited by this paper
• Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

  2019cited by this paper
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

  2018cited by this paper
• CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

  2018cited by this paper
• The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

  2016cited by this paper
• Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

  2015cited by this paper
• Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

  2012cited by this paper

• Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

  2026cites this paper
• Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer

  2026cites this paper